PHD finger protein 7Genealiases: HSPC045 · HSPC226 · NYD-SP6
Q-omics provides the consensus-scored PHF7 profile across patient tissues and cancer cell-line models. PHF7 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, PHF7 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, PHF7 RNA expression shows 19,666 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KIRC, and UVM as cancer lineages where PHF7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHF7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHF7 survival associations across molecular data types. PHF7 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHF7 RNA expression–survival associations across cancer types. High PHF7 expression shows favorable associations in BRCA, KIRP, PAAD, UCS, ACC and READ. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for PHF7 RNA expression.
This table summarizes PHF7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PHF7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHF7 shows lower tumor expression in KIRC, COAD, BRCA and READ and higher tumor expression in LIHC and KICH. The KIRC box plot shows higher PHF7 RNA expression in normal versus tumor tissue (log2 FC = −0.386, t-test p < 0.001).
This table shows molecular features associated with PHF7 in patient tissues and cancer cell lines. In patient samples, PHF7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PHF7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
